表紙
市場調査レポート

免疫学関連の各種提携契約:契約条件・合意内容

Global Immunology Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 250302
出版日 ページ情報 英文 1000+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
免疫学関連の各種提携契約:契約条件・合意内容 Global Immunology Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年02月01日 ページ情報: 英文 1000+ Pages
概要

当レポートでは、2007年以降の免疫学関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 免疫学関連の各種契約の動向

  • イントロダクション
  • 過去数年における免疫学関連の提携
  • 大手製薬会社による契約活動
  • 免疫学関連の事業に積極的でない大手製薬会社
  • 免疫学関連の提携:契約タイプ別
  • 免疫学関連の提携:産業部門別
  • 免疫学関連の提携:開発ステージ別
  • 免疫学関連の提携:技術タイプ別
  • 免疫学関連の提携:適応症別
  • 平均契約期間

第3章 主要契約

  • イントロダクション
  • 主要契約:取引額別
  • 大手製薬会社のかかわる主要契約

第4章 大手製薬会社による契約

  • イントロダクション
  • 大手製薬会社による提携契約の利用法
  • 企業プロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 契約タイプ別
    • 資産購入
    • 譲渡
    • 大手によるアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同販売
    • サービス契約
    • 共同プロモーション
    • クロスライセンス
    • 流通
    • 株式購入
    • ジョイントベンチャー
    • ライセンシング
    • 訴訟
    • ローン
    • 製造
    • マーケティング
    • オプション
    • プロモーション
    • 研究
    • 和解関連
    • スピンアウト
    • サブライセンス
    • 供給
    • 終了
  • 開発ステージ別
    • 創薬
    • 製剤
    • フェーズI
    • フェーズII
    • フェーズIII
    • 前臨床
    • 規制
  • 技術タイプ別
    • 抗体
    • アッセイ
    • 生物学的化合物
    • 細胞治療
    • デバイス
    • 創薬ツール
    • イネーブリング技術
    • 設備
    • 装置
    • ゲノミクス
    • インビトロモデル
    • 天然製品
    • オリゴヌクレオチド
    • 希少薬
    • パッケージング
    • ペプチド
    • 加工
    • プロテオミクス
    • 組み換えDNA
    • RNA治療
    • スクリーニング
    • 小分子
    • 幹細胞
    • ワクチン

第6章 免疫学関連の契約:適応症別

  • イントロダクション
  • 適応症別
    • 免疫学
    • AIDS
    • アレルギー
    • アナフィラキシーショック
    • 移植片対宿主拒絶反応(GVHD)
    • 炎症
    • 全身性エリテマトーデス(SLE)
    • 硬皮症

第7章 提携機会

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2224

The Global Immunology Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the immunology/autoimmune partnering deals and agreements entered into by the worlds leading healthcare companies

Global Immunology Partnering 2010 to 2016 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Immunology partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Immunology partnering agreement structure
  • Immunology partnering contract documents
  • Top Immunology deals by value
  • Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2010. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope

Global Immunology Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

Global Immunology Partnering 2010 to 2016 includes:

  • Trends in Immunology dealmaking in the biopharma industry since 2010
  • Analysis of Immunology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Immunology deal contract documents
  • Comprehensive access to over 3500 Immunology deal records
  • The leading Immunology deals by value since 2010
  • Most active Immunology dealmakers since 2010

In Global Immunology Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 700 immunology deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Immunology Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Immunology deal trends since 2010
  • Access Immunology deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Immunology partner companies
  • Comprehensive access to over 750 links to actual Immunology deals entered into by the world's biopharma companies
  • Indepth review of Immunology deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Immunology opportunities
  • Uncover companies actively partnering Immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

  • 2.1. Introduction
  • 2.2. Immunology partnering over the years
  • 2.3. Immunology partnering by deal type
  • 2.4. Immunology partnering by industry sector
  • 2.5. Immunology partnering by stage of development
  • 2.6. Immunology partnering by technology type
  • 2.7. Immunology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Immunology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Immunology partnering
  • 3.3. Immunology partnering headline values
  • 3.4. Immunology deal upfront payments
  • 3.5. Immunology deal milestone payments
  • 3.6. Immunology royalty rates

Chapter 4 - Leading Immunology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Immunology partnering
  • 4.3. List of most active dealmakers in Immunology
  • 4.4. Top Immunology deals by value

Chapter 5 - Immunology contract document directory

  • 5.1. Introduction
  • 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Immunology therapeutic target

Appendices

  • Appendix 1 - Directory of Immunology deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Immunology deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Immunology deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Immunology deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Immunology partnering since 2010
  • Figure 2: Immunology partnering by deal type since 2010
  • Figure 3: Immunology partnering by industry sector since 2010
  • Figure 4: Immunology partnering by stage of development since 2010
  • Figure 5: Immunology partnering by technology type since 2010
  • Figure 6: Immunology partnering by indication since 2010
  • Figure 7: Immunology deals with a headline value
  • Figure 8: Immunology deals with upfront payment values
  • Figure 9: Immunology deals with milestone payment
  • Figure 10: Immunology deals with royalty rates
  • Figure 11: Active Immunology dealmaking activity- 2010 to 2016
  • Figure 12: Top Immunology deals by value since 2010
Back to Top